---
layout: default
title: Ropivacaine Hcl
parent: 僅模型預測 (L5)
nav_order: 179
evidence_level: L5
indication_count: 0
---

# Ropivacaine Hcl
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ropivacaine HCL: Local Anaesthetic — No TxGNN Repurposing Prediction Available

## One-Sentence Summary

Ropivacaine HCL is an amide-type local anaesthetic used for regional and epidural anaesthesia. The current Evidence Pack contains **no TxGNN-predicted indications** for this drug, indicating either a mapping failure or that the drug was not successfully linked to the TxGNN knowledge graph. With **zero clinical trials** and **zero publications** returned in this evidence pack, a full repurposing evaluation cannot be completed at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Regional anaesthesia (amide-type local anaesthetic — based on known pharmacology; not captured in this Evidence Pack) |
| Predicted New Indication | No prediction available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only (no prediction generated) |
| UK Market Status | Not recorded (Evidence Pack shows no marketing authorisations; likely a data collection gap) |
| Number of Marketing Authorisations | 0 (as recorded in this Evidence Pack) |
| Recommended Decision | **Hold** |

---

## Safety Considerations

All safety fields in this Evidence Pack are absent. Please refer to the **Summary of Product Characteristics (SmPC)** for Naropin® (ropivacaine) and the **British National Formulary (BNF) Section 15.2** for full prescribing information. Report any suspected adverse reactions via the **Yellow Card Scheme** at [yellowcard.mhra.gov.uk](https://yellowcard.mhra.gov.uk).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack contains no TxGNN-predicted indications, no DrugBank identifier, no UK marketing authorisation records, and no safety data — none of the minimum data fields required for a repurposing evaluation are present. Submission of this drug to the repurposing pipeline appears to have stalled at the data ingestion stage.

**To proceed, the following is needed:**

- **Resolve DrugBank mapping failure**: The DrugBank query returned 1 result but no DrugBank ID was captured. Manually confirm the DrugBank ID for ropivacaine (likely DB00296) and re-run the pipeline.
- **Re-run TxGNN prediction**: Once the DrugBank ID is confirmed, re-execute the KG and DL prediction steps (`run_kg_prediction.py`) to generate candidate indications.
- **Populate UK market authorisation data**: Verify MHRA authorisation records for ropivacaine (brand: Naropin®, PL 17901/0080 and related). The current Evidence Pack records zero authorisations, which is inconsistent with the drug's known UK market presence.
- **Retrieve SmPC safety data**: Download and parse the ropivacaine SmPC from the MHRA product database to populate warnings, contraindications, and drug interaction fields.
- **Confirm original indication mapping**: `original_indications` is currently empty. Populate with approved indication text (e.g., surgical anaesthesia, acute pain management, epidural analgesia in labour) to enable mechanistic plausibility analysis.
- **Re-submit for full evaluation** once the above data gaps (DG001 — MHRA SmPC warnings; DG002 — mechanism of action) have been resolved.

---

> **Disclaimer:** This report is for research reference only and does not constitute medical advice. Any drug repurposing candidates identified require clinical validation before use. This report was generated using available data as of 2026-04-04.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

